AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis-Reference-Cited by-同舟云学术

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Published:2017-08-03 Issue:5 Volume:130 Page:632-642
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Dittrich Tobias¹²^ORCID,Bochtler Tilmann¹²³,Kimmich Christoph¹²,Becker Natalia⁴,Jauch Anna⁵,Goldschmidt Hartmut²⁶,Ho Anthony D.²,Hegenbart Ute¹²,Schönland Stefan O.¹²

Affiliation:

1. Amyloidosis Center and

2. Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany;

3. Clinical Cooperation Unit Molecular Hematology/Oncology and

4. Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany;

5. Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany; and

6. National Center of Tumor Diseases, Heidelberg, Germany

Abstract

Key PointsAL patients with an initial dFLC <50 mg/L represent a distinct clinical subgroup with mostly renal disease and a favorable prognosis. These patients are evaluable for hematologic response including a novel low-dFLC partial response, which predict renal and overall survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/5/632/1404181/blood767475.pdf

Reference23 articles.

1. Recent advances in the management of AL Amyloidosis;Kastritis;Br J Haematol,2016

2. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis;Abraham;Am J Clin Pathol,2003

3. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis;Bochtler;Haematologica,2008

4. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains;Katzmann;Clin Chem,2002

5. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine;Palladini;Clin Chem,2009

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of B cell maturation antigen‐directed CAR T‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis;European Journal of Haematology;2024-08-27

2. Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis;JAMA Cardiology;2024-08-21

3. Clinical Use of Biomarkers in Cardiac Amyloidosis;Heart Failure Clinics;2024-07

4. Влияние поражения сердца на прогноз у пациентов с системным AL-амилоидозом;Clinical Oncohematology;2024-07-01

5. The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review;Blood Advances;2024-06-28